Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
  • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
  • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents

Definitions

• the present invention relates to a therapeutic agent for the treatment of mastitis in livestock, and a method for treating mastitis using the same. Particularly, the present invention relates to a therapeutic agent and method for the treatment of mastitis in livestock during lactation periods.
• Mammals described as livestock for example, cattle, horses, goats, sheep, pigs and rabbits, all possess a mammary gland and therefore may develop mastitis.
• Livestock that are frequently milked for example, cattle and in particular the milk cow, are most liable to develop mastitis.
• Mastitis is one of the most difficult diseases to cure for the milk cow. Mastitis tends occur more frequently in recent years due to milking stress as a result of large scale breeding of cows and wide spread use of milking machines. Consequently, the mammae of cows often develop mastitis, with an incidence of as high as 1 ⁇ 4 of the total milk cows, including subclinical cows.
• somatic cell counts SCC in the raw milk of a healthy cow.
• SCC in the raw milk of a cow with mastitis reportedly increases to 1,600,000 cells/mL or more.
• the milk production of the cow decreases by 0.4 kg a day and 0.6 kg a day in primipara cow and multipara cow, respectively, for every increase of twice as much as SCC of 50,000 cells/mL or less.
• the fat content of the raw milk is also reported to decrease at a rate of 0.2 g/kg for every increase of twice as much as SCC (Am. J. Vet. Res., vol. 29, 497, 1968).
• Mastitis is a highly intractable disease, firstly because it is induced by a variety of microorganisms.
• Representative causative microorganisms include Staphylococcus aureus, Streptococcus agalactiae, Streptococcus dysgalactiae, Escherichia coli and Corynebacterium pyogenes. Infection by these microorganisms is triggered by the stress such as large-scale breeding and wide spread use of the milking machines on the cow. Therefore, the number of infected cow is increasing each year.
• a second reason for the intractability of mastitis is that because it is considered along with other microbial diseases, and protection from mastitis relies too much on the use of highly potent antibiotics. Too much reliance on the antibiotics tends to neglect the importance of studies of pathological mechanisms of the onset of the disease and chronic infection mechanisms. It has been common means of treatment to select from and inject antibacterial agents such as furan and sulfur agents and antibiotics such as penicillin, sefem, streptomycin, tetracycline and macrolide based antibiotics.
• these antibacterial substances may affect human health because the resistant bacteria occur due to residual antibacterial substances in the milk. Consequently, the period of use of these antibacterial substances is strictly restricted. Use of these antibacterial substances is also strictly restricted worldwide by a variety of regulations. Therefore, medication is often forced to be interrupted, even before sufficient remedial effects are achieved. As a result, dairy farmers are often troubled by recurrence of the disease and within a short time have to resume of medication.
• a third reason for the intractability of mastitis is that the immune system of the mammary gland of milk cow differs according to the secretion and non-secretion periods of the milk secretion cycle (Vet. Immunol. & Immunopathol., vol. 65, 51-61, 1998; J. Diary Sci., vol. 82, 1459-1464, 1999). This may in fact be the main cause of the intractability of mastitis. That is, the modes of microbial infection in the mammary gland tissue are different, and infection protection mechanisms of the mammary gland itself may be very different during these periods.
• the cells in the mammary gland and the immune system in the secreted milk is mainly composed of CD8 t T-cells and ⁇ t T-cells that by themselves control epithelium cells concerning secretion of the milk. Accordingly, the immune function during this milk secretion period mainly operates by the cell-mediated immunity of Th1 (a group of helper T-cells).
• the cells in the mammary gland and milk during the non-secretion dry period are mainly composed of leukocytes, CD4 t T-cells and B cells originating from the blood and spinal cord. Accordingly, the immune function mainly operates by phagocytic response and humoral immunity mainly comprising antibodies and complements.
• both periods involve quite contrasting immune mechanisms, and perform quite contrasting methods of protection against infection. Therefore, measures for protecting the animal from infection should naturally be different according to these periods. However, these features have not been taken into consideration in conventional countermeasures against infection.
• Glycyrrhizin has been reported as having a variety of immunological functions in experimental animals such as mice. For example, glycyrrhizin stimulates the lymphocytes and induces production of IFN (interferon, Microbial. Immunol., vol. 26, 535-539, 1982) to enhance killer activities of the NK (natural killer) cells (Excerpta Medica International Conference Series, vol. 641, 460-464, 1983).
• glycyrrhizin is known to facilitate activation of the extra-thymus differentiated T-cells including ⁇ t T-cells and CD8 t T-cells that are selectively distributed in the intestinal tract and mucosal organs independently of the thymus of the mouse (Biotherapy, vol. 5, 167-176, 1992). Otherwise, glycyrrhizin is known to facilitate a boost-up of cellular immunity based on the activation of the helper T-cells (in particular Th1 helper cells), thereby participating in protection of various virus infection diseases including retrovirus infection (Biotherapy, vol. 9, 209-220. 1996) and the suppression of allergic responses of the skin.
• helper T-cells in particular Th1 helper cells
• Glycyrrhizin with protective effects against herpes virus induced death of the mucosal membrane has also been proven to enhance immune activity with glycyrrhizin in a mouse with immune deficiency that the skin is being burned.
• glycyrrhizin has been used as an anti-inflammatory agent for external use on the human skin (Japanese Patent Laid-open No. 6-305932).
• glycyrrhizin has been used as a human nasal absorption drug as an absorption-accelerating agent (Drug Delivery System, vol. 4, 88-93, 1989).
• the present invention provides a therapeutic agent against mastitis in livestock, comprising glycyrrhizin or the pharmaceutically acceptable salts thereof as effective ingredients.
• the present invention also provides a therapeutic agent against mastitis in livestock, comprising glycyrrhizin or the pharmaceutically acceptable salts thereof as effective ingredients for use during the milk secretion period.
• the present invention further provides a therapeutic agent against mastitis in livestock, comprising administering glycyrrhizin or the pharmaceutically acceptable salts thereof into the mammae of the livestock.
• the present invention further provides a therapeutic method for the treatment of mastitis in livestock, comprising directly injecting glycyrrhizin or pharmaceutically acceptable salts thereof into the mammae of the livestock.
• the present invention further provides a therapeutic method for the treatment of mastitis in livestock, comprising administering glycyrrhizin or pharmaceutically acceptable salts thereof into the mammae of the livestock during the milk secretion period.
• the present invention further provides a therapeutic method for the treatment of mastitis in livestock, comprising directly administering glycyrrhizin or pharmaceutically acceptable salts thereof into the mammae of the livestock during the milk secretion period.
• the present invention further provides a therapeutic method for the treatment of mastitis in livestock, comprising directly injecting glycyrrhizin or pharmaceutically acceptable salts thereof into the mammae of the livestock during the milk secretion period.
• the present invention further provides the therapeutic agent or therapeutic method, wherein the livestock includes cattle.
• the present invention further provides a therapeutic method for mastitis comprising directly injecting glycyrrhizin or pharmaceutically acceptable salts thereof into the mammae of cattle using a cannula.
• the present invention provides therapeutic agents and therapeutic methods for treating mastitis of the livestock. Particularly, the present invention provides therapeutic agents for the treatment of mastitis during the milk secretion period of livestock. In addition, using glycyrrhizin or its salt that are commonly used as a food additive for humans alleviates human safety problems.
• the effective ingredient of the therapeutic agent for the treatment of mastitis according to the present invention comprises glycyrrhizin, represented by the following formula, or pharmaceutically acceptable salts thereof.
• Glycyrrhizin (glycyrrhizinic acid) to be used in the present invention is obtained by extracting the root and stolon of Glycyrrhiza (Glycyrrhiza uralensis Fisher, Glycyrrhiza Glabra Linne) or plants belonging to the same genus as Glycyrrhiza (Glycyrrhiza inflata Batalin, Glycyrrhiza korshinsky G. Grig., et al.) with a glycyrrhizin soluble solvent such as water, methanol, ethanol and n-butanol. Commercially available glycyrrhizin may be used.
• Pharmacologically acceptable salts include ammonium and alkali metal salts of glycyrrhizin or a choline salt of glycyrrhizin obtained by reacting glycyrrhizin and an inorganic or organic base at a 1:1, 1:2 or 1:3 molar ratio.
• the salts are not necessarily restricted to those described above so long as the safety of the cow and the dairy farmer is ensured.
• Glycyrrhizin alone or any plural combination of salts thereof may be formulated as effective ingredients of the therapeutic agent.
• Glycyrrhizin derivatives obtained by a conventional chemical synthesis using glycyrrhizin as a starting material may be used as the effective ingredient of the therapeutic agent, so long as they are effective for the treatment of mastitis.
• Formulations containing these effective ingredients comprise an ointment in which glycyrrhizin or its salt is uniformly dispersed in an ointment base, or a liquid preparation prepared by dissolving glycyrrhizin or its salt in water or ethanol. These formulations may be manufactured using conventional arts. A therapeutic agent containing commercially available glycyrrhizin may be used.
• Examples of the ointment base to be used for preparing the ointment include, though not restrictive, hydrophobic ointment bases such as white petrolatum, yellow petrolatum, liquid paraffin, olive oil, peanuts oil, soybean oil and lanolin; and hydrophilic ointment bases such as polyethylene glycol, sodium polyacrylate, stearyl alcohol, stearic acid, aluminum stearate, glycerin, sodium arginate and carboxymethyl cellulose.
• hydrophobic ointment bases such as white petrolatum, yellow petrolatum, liquid paraffin, olive oil, peanuts oil, soybean oil and lanolin
• hydrophilic ointment bases such as polyethylene glycol, sodium polyacrylate, stearyl alcohol, stearic acid, aluminum stearate, glycerin, sodium arginate and carboxymethyl cellulose.
• the solvents to be used for the liquid preparation include, though not restrictive, polypropylene glycol, polyethylene glycol and glycerin in addition to those described above.
• Additives such as a buffer agent, an osmotic pressure adjustment agent, a stabilizer and an antiseptic may also be added.
• Glycyrrhizin and other ingredients that will be left in the raw milk have no adverse effects on the human health, since the therapeutic agent according to the present invention contains glycyrrhizin and other ingredient that are commonly used as food additives for humans.
• the agent is particularly effective for the cattle during its milk secretion period.
• the total dosage of glycyrrhizin and its salt is preferably 400 to 800 mg per mamma.
• the therapeutic agent is preferably administered to have a glycyrrhizin concentration in the milk of 0.08 to 0.4 mg/mL. These values have been determined by converting the dosage for humans into the volume of the milk in the mammae.
• the agent may be administered once, twice or more a day. Or, it may be administered every few days.
• the therapeutic agent is directly injected into the mammae as an ointment or liquid preparation.
• a cannula and a syringe are used for injection, use of the cannula is preferable considering the volume being administered.
• Therapeutic tests were performed in seven cases of clinical type mastitis of Holstein cow using a glycyrrhizin therapeutic agent (High Efficiency Kaneo-Minofagen C made by Minofagen Pharmaceutical Industries Co.) using the method described in the following Examples 1 to 5, 6 and 7.
• a glycyrrhizin therapeutic agent High Efficiency Kaneo-Minofagen C made by Minofagen Pharmaceutical Industries Co.
• a therapeutic composition containing glycyrrhizin shown below was dissolved into water to a final volume of 1000 mL, and its pH and osmotic pressure were adjusted to 6.7 and 2, respectively, in order to prepare a therapeutic agent of the invention.
• the formulation of the herapeutic composition is shown below.
• the therapeutic agent containing 400 mg equivalence glycyrrhizin was administered into the mamma manifesting mastitis using a cannula on day zero of recognition of the disease.
• the results of treatment were evaluated on day 0, 1 to 3, 7, 14 and 21, which will be described hereinafter. These results are shown in Tables 1 to 5.
• CMT California Mastitis Test
• ⁇ The mamma shows slight rigidity.
• ⁇ The mamma shows no inflation and rigidity.
• [0070] ++ The size and number of the aggregates are large. The number of the aggregates is three or more per mL.
• the number of the aggregates is small, although the size is large.
• the number of the aggregates is 0.5 to 3 per mL.
• ⁇ The size and number of the aggregates are small. The number of the aggregates is smaller than 0.5 per mL.
• the degree of coagulation of the milk was judged following the modified CMT method using a commercially available test kit (PL tester made by Nihon Zenyaku Co.). Two ml of the milk was sampled from each mamma into the plate of the test kit, and an equal volume of the modified CMT reagent was added to each plate. After gently turn the plate for one minute in order to mix the sample and reagent, the degree of coagulation was judged.
• PL tester made by Nihon Zenyaku Co.
• ⁇ The milk flows smoothly irrespective of a small degree of coagulation.
• SCC was measured by allowing the cells to remain at 4° C. after mixing the milk with ethanol.
• the cells were stained with Propidium Iodide (PI), and the number of the positive cells was measured using FACS Calibur (Becton-Dickinson) (J. Livestock Society, vol. 70, J169-176, 1999).
• the number of PMN in the milk was measured using a microscope, whereby the cells were counted under a microscope by Giemsa staining after washing the milk a phosphate buffered saline (PBS) and adhering the cells to a slide glass using Cytospin (made by Shandon Scientific Ltd.) (J. Livestock Society, vol. 70, J169-176, 1999).
• PBS phosphate buffered saline
• Example 1 Days after the start of treatment Day Day Day Day Day 0 1 2 7 14 21 Clinical Inflation and + + ⁇ ⁇ ⁇ ⁇ diagnosis rigidity of the mamma Aggregates in + + ⁇ ⁇ ⁇ ⁇ the milk Test of Degree of ++ ⁇ ⁇ ⁇ ⁇ ⁇ the milk coagulation of the milk (modified CMT method) Judgment by ⁇ ⁇ ⁇ ⁇ ⁇ pH of the milk (modified CMT method) Number of 416 215 88 7 2 0.3 somatic cells in the milk (SCC ⁇ 10 4 cells/mL) Number of 359 173 58 3 0.6 Nt granulocytes in the milk (PMN ⁇ 10 4 cells/mL) Causative Gram positive bacillus microorgan- isms
• the measured “degree of coagulation of the milk” and “judgment by pH of the milk” according to modified CMT methods referred to as “measured CMT” hereafter
• the measured “number of the somatic cells” were rapidly improved after the administration of glycyrrhizin. Disease conditions also disappeared 2 days after administration, and recovered enough for distribution of the milk 4 days after administration.
• Example 7 Results of Example 7 Days after the start of treatment Day Day Day Day Day Day 0 1 2 7 14 21 Clinical Inflation and ++ + ⁇ ⁇ ⁇ ⁇ diagnosis rigidity of the mamma Aggregates in ++ ⁇ ⁇ ⁇ + ⁇ the milk Test of Degree of ++ ⁇ ⁇ ⁇ ++ ⁇ the milk coagulation of the milk (modified CMT method) Judgment by ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ pH of the milk (modified CMT method) Number of 499 1080 673 459 700 45 somatic cells in the milk (SCC ⁇ 10 4 cells/mL) Number of Nt Nt Nt Nt Nt Nt granulocytes in the milk (PMN ⁇ 10 4 cells/mL) Causative Coagulase positive Staphylococcus aureus and microorgan- hemolytic Gram positive bacillus isms
• Cows manifesting clinical type mastitis were treated with antibiotics mainly comprising Sephazon formulations as a comparative drug in the six cases of treatment of the Holstein milk secreting cows shown in Comparative examples 1 to 6 below.
• the observed results of “degree of coagulation of the milk” in the Comparative Examples 1 to 6 are shown in Table 9.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Molecular Biology (AREA)
• Reproductive Health (AREA)
• Rheumatology (AREA)
• Communicable Diseases (AREA)
• Gynecology & Obstetrics (AREA)
• Pregnancy & Childbirth (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Endocrinology (AREA)
• Pain & Pain Management (AREA)
• Oncology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Saccharide Compounds (AREA)

Priority Applications (1)

Applications Claiming Priority (4)

Related Child Applications (1)

Publications (1)

Family

ID=26604550

Family Applications (2)

Family Applications After (1)

Country Status (6)

Cited By (6)

Families Citing this family (35)

Family Cites Families (8)

• 2001
  • 2001-02-22 JP JP2001046565A patent/JP3435405B2/ja not_active Expired - Lifetime
  • 2001-11-23 CA CA002363990A patent/CA2363990C/fr not_active Expired - Lifetime
  • 2001-11-23 DE DE60113496T patent/DE60113496T2/de not_active Expired - Lifetime
  • 2001-11-23 EP EP01127408A patent/EP1208844B1/fr not_active Expired - Lifetime
  • 2001-11-23 ES ES01127408T patent/ES2246282T3/es not_active Expired - Lifetime
  • 2001-11-26 US US09/995,040 patent/US20020115622A1/en not_active Abandoned
• 2003
  • 2003-07-28 US US10/629,117 patent/US6872709B2/en not_active Expired - Lifetime

Also Published As

Similar Documents

Legal Events